EGFR and non-small cell lung carcinoma: In the phase 3 ADAURA study of 682 patients with stage IB–IIIA NSCLC with an EGFR mutation, patients were randomly assigned to receive adjuvant osimertinib 80 mg daily for up to 3 years versus placebo [95,96].